Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments

• KOHLER GI, BODE-BOGER SM, BUSSE R, HOOPMANN M, WELTE T, BOGER RH: Drug–drug interactions in medical patients: effects of in hospital treatment and relation to multiple drug use. Int. J. Clin. Pharmacol. Ther. (2000) 38(11):504-513.
   PubMed Web of Science ®Google Scholar
• VON EULER M, ELIASSON E, OHLEN G, BERGMAN U: Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiol. Drug Saf. (2006) 15(3):179-184.
   PubMed Web of Science ®Google Scholar
• MERLE L, LA-ROCHE ML, DANTOINE T, CHERMES JP: Predicting and preventing adverse reactions in the very old. Drugs Aging (2005) 22(5):375-392.
   PubMed Web of Science ®Google Scholar
• VENTAKATAKRISHNAN K, VON MOLTKE LL, GREENBLATTA DJ: Effects of the antifungals agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. (2000) 38(2):111-180.
   PubMed Web of Science ®Google Scholar
• VANDEL P: Antidepressant drugs in the elderly – role of the cytochrome P450 2D6. World J. Biol. Psychiatry. (2003) 4(2):74-80.
   PubMed Web of Science ®Google Scholar
• BRUCE RD, ALTICE FL, GOUREVITCH MN, FRIEDLAND GH: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune. Defic. Syndr. (2006) 41(5):563-572.
   PubMed Web of Science ®Google Scholar
• HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The International Classification of Headache Disorders, 2nd edition. Cephalalgia (2004) 24(Suppl. 1):9-160.
   PubMed Web of Science ®Google Scholar
• PRYSE-PHILLIPS WEM, DODICK DW, EDMEADS JG et al.: Guidelines for the diagnosis and management of migraine in clinical practice. Can. Med. Assoc. J. (1997) 156:1273-1287.
   PubMed Web of Science ®Google Scholar
• DANISH NEUROLOGICAL SOCIETY AND THE DANISH HEADACHE SOCIETY: Guidelines for the management of headache. Cephalalgia (1998) 18:9-22.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD: Practice parameter: evidenced-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Committee of the American Academy of Neurology. Neurology (2000) 55:754-763.
   PubMed Web of Science ®Google Scholar
• ITALIAN SOCIETY FOR THE STUDY OF HEADACHES: Diagnostic and therapeutic guidelines for migraine and cluster headache. J. Headache Pain (2001) 2:105-192.
   Google Scholar
• AMERICAN ACADEMY OF FAMILY PHYSICIANS AND THE AMERICAN COLLEGE OF PHYSICIANS – AMERICAN SOCIETY OF INTERNAL MEDICINE: Clinical Guidelines for the Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache. Ann. Intern. Med. (2002) 137:840-849.
   PubMed Web of Science ®Google Scholar
• GERAUD G, LANTERI-MINET M, LUCAS C, VALADE D on behalf of the French Society for the Study of Migraine Headache (SFEMC): French guidelines for the diagnosis and managements of migraine in adults and children. Clin. Ther. (2004) 26(8):1305-1318.
   PubMed Web of Science ®Google Scholar
• SCHUURMANS A, VAN-WEEL C: Pharmacological treatment of migraine. Comparison of guidelines. Can. Fam. Physician (2005) 51:838-843.
   PubMed Web of Science ®Google Scholar
• DU-SOUICH P: In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can. J. Clin. Pharmacol. (2001) 8(3):153-161.
   PubMedGoogle Scholar
• JANCHWEE B, OWATRANPORN T, MAHATTHANATRAKUL W, CHONGSUVIVATWONG V: Clinical drug interactions in outpatients of a university hospital in Thailand. J. Clin. Pharm. Ther. (2005) 30(6):583-590.
   PubMed Web of Science ®Google Scholar
• REGARDH CG, LUNDBORG P, PERSSON BA: The effect of antacid, metoclopramide and propantheline on the bioavailability of metoprolol and atenolol. Biopharm. Drug Dispos. (1981) 2:79-87.
   PubMed Web of Science ®Google Scholar
• MUTSCHLER E, SPAHN H, KIRCH W: The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br. J. Clin. Pharmacol. (1984) 17(Suppl 1):51-57.
   PubMedGoogle Scholar
• SEIDEMAN P, BORG KO, HAGLUND K et al.: Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension. Br. J. Clin. Pharmacol. (1987) 23:267-271.
   PubMed Web of Science ®Google Scholar
• KIRCH W, GORG KG: Clinical pharmacokinetics of atenolol – a review. Eur. J. Drug Met. Pharmacokinet. (1982) 7:81-91.
   PubMed Web of Science ®Google Scholar
• BUHRING KU, SAILER H, FARO HP et al.: Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. J. Cardiovasc. Pharmacol. (1986) 8(Suppl 11):21-28.
   PubMed Web of Science ®Google Scholar
• PRAKASH A, MARKHAM A: Metoprolol. A review of its use in chronic heart failure. Drugs (2000) 60(3):647-678.
   PubMed Web of Science ®Google Scholar
• MCCOLLUM DL, GREENE JL, MCGUIRE DK: Severe sinus bradycardia after initiation of bupropion therapy: a probable drug–drug interaction with metoprolol. Cardiovasc. Drugs Ther. (2004) 18:329-330.
   PubMed Web of Science ®Google Scholar
• Product information: Lexapro®, escitalopram oxalate tablet, oral solution. Forest Pharmaceuticals, St. Louis, MO, USA (2005).
   Google Scholar
• HAMELIN B, BOUAYAD A, METHOT J et al.: Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmacol. Ther. (2000) 67:466-477.
   PubMed Web of Science ®Google Scholar
• HEMERYCK A, LEFEBVRE RA, DE VRIENDT C, BELPAIRE FM: Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin. Pharmacol. Ther. (2000) 67(3):283-291.
   PubMed Web of Science ®Google Scholar
• LUNDBORG P, REGARD CG: The effect of propoxyphene pretreatment on the disposition of metoprolol and propranolol. Clin. Pharmacol. Ther. (1981) 29:263-264.
   Google Scholar
• Product information: Norvir®, ritonavir. Abbott Laboratories, North Chicago, IL, USA (2000).
   Google Scholar
• Product information: Ketek™, telithromycin. Aventis Pharmaceuticals, Kansas City, MO, USA (2004).
   Google Scholar
• MORRISON RA, SINGHVI SM, CREASEY WA et al.: Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects. Eur. J. Clin. Pharmacol. (1988) 33:625-628.
   PubMed Web of Science ®Google Scholar
• NACE GS, WOOD AJ: Pharmacokinetics of long acting propranolol. Implications for therapeutic use. Clin. Pharmacokinet. (1987) 13(1):51-64.
   PubMed Web of Science ®Google Scholar
• SOWINSKI KM, BURLEW BS: Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Pharmacotherapy (1997) 17:1305-1310.
   PubMed Web of Science ®Google Scholar
• KAILA T, KARHUVAARA S, HUUPPONEN R et al.: The analysis of plasma kinetics and beta-receptor binding and -blocking activity of timolol following its small intravenous dose. Int. J. Clin. Pharmacol. Ther. Toxicol. (1993) 31:351-357.
   PubMedGoogle Scholar
• LENNARD MS, TUCKER GT, SILAS JH et al.: Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenbiotica (1986) 16:435-447.
   PubMed Web of Science ®Google Scholar
• SICA DA: Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J. Clin. Hypertens. (2005) 7(Suppl. 1):21-26.
   PubMedGoogle Scholar
• CASTANEDA-HERNANDEZ G, VARGAS-ALVARADO Y, AGUIRRE F et al.: Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. Arzneimittelforschung (1993) 43:539-542.
   PubMed Web of Science ®Google Scholar
• NARIMATSU S, KARIYA S, ISOZAKI S et al.: Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. Biochem. Biophys. Res. Commun. (1993) 193(3):1262-1268.
   PubMed Web of Science ®Google Scholar
• BIALER M: Comparative pharmacokinetics of the newer antiepileptic drugs. Clin. Pharmacokinet. (1993) 24(6):441-452.
   PubMed Web of Science ®Google Scholar
• LIU XQ, REN YL, QIAN ZY, WANG GJ: Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol. Sin. (2000) 21(8):690-694.
   PubMed Web of Science ®Google Scholar
• BLARDI P, URSO R, DE-LALLA A, VOLPI A, PERRI TD, AUTERI A: Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin. Pharmacol. Ther. (2002) 72(5):556-561.
   PubMed Web of Science ®Google Scholar
• HE Z, ZHONG D, CHEN X, LIU X, TANG X, ZHAO L: Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur. J. Pharm. Sci. (2004) 21(4):487-491.
   PubMed Web of Science ®Google Scholar
• ANDERSON P, BONDESSON U, SYLVEN C: Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. Eur. Clin. Pharmacol. (1982) 23:49-57.
   Web of Science ®Google Scholar
• LEMMA GL, WANG Z, HAMMAN MA, ZAHEER NA, GORSKI JC, HALL SD: The effect of short and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin. Pharmacol. Ther. (2006) 79(3):218-230.
   PubMed Web of Science ®Google Scholar
• KATES RE, KEEFE DL, SCHWARTZ J: Verapamil disposition kinetics in chronic atrial fibrillation. Clin. Pharmacol. Ther. (1981) 30:44-51.
   PubMed Web of Science ®Google Scholar
• RUDORFER MV, POTTER WZ: Metabolism of tricyclic antidepressants. Cell. Mol. Neurobiol. (1999) 19(3):373-409.
   PubMed Web of Science ®Google Scholar
• BERTILSSON L, DAHL ML, TYBRING G: Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr. Scand. Suppl. (1997) 391:14-21.
   PubMedGoogle Scholar
• VENKATAKRISHNAN K, VON-MOLTKE LL, OBACH RS, GREENBLATT DJ: Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J. Pharmacol. Exp. Ther. (2000) 293(2):343-350.
   PubMed Web of Science ®Google Scholar
• MARTENSSON E, AXELSSON R, NYBERG G et al.: Pharmacokinetic properties of the antidepressant drugs amitriptyline, clomipramine, and imipramine: a clinical study. Curr. Therap. Res. (1984) 36:228-238.
   Web of Science ®Google Scholar
• ARMSTRONG SC, COZZA KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics (2003) 44(2):167-171.
   PubMed Web of Science ®Google Scholar
• AMSTERDAM J, BRUNSWICK D, MENDELS J: The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am. J. Psychiatry (1980) 137:653-662.
   PubMed Web of Science ®Google Scholar
• GILLMAN PK: Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum. Psychopharmacol. (2005) 20(1):61-62.
   PubMed Web of Science ®Google Scholar
• MOODY JP, WHYTE SF, MACDONALD AJ, NAYLOR GJ: Pharmacokinetic aspects of protriptyline plasma levels. Eur. J. Clin. Pharmacol. (1977) 11(1):51-56.
   PubMed Web of Science ®Google Scholar
• VANDEL P, HAFFEN E, NEZELOF S, BROLY F, KANTELIP JP, SECHTER D: Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. Hum. Psychopharmacol. (2004) 19(5):293-298.
   PubMed Web of Science ®Google Scholar
• BALANT-GORGIA AE, GEX-FABRY M, BALANT LP: Clinical pharmacokinetics of clomipramine. Clin. Pharmacokinet. (1991) 20:447-462.
   PubMed Web of Science ®Google Scholar
• LANCASTER SG, GONZALEZ JP: Dothiepin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs (1989) 38:123-147.
   PubMed Web of Science ®Google Scholar
• STEINER TJ, AHMED F, FINDLEY LJ, MACGREGOR EA, WILKINSON M: S-fluoxetine in the prophylaxis of migraine: a Phase II double-blind randomized placebo-controlled study. Cephalalgia (1998) 18:283-286.
   PubMed Web of Science ®Google Scholar
• BANK J: A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache (1994) 34(8):476-478.
   PubMed Web of Science ®Google Scholar
• HAYS P: Paroxetine prevents migraines. J. Clin. Psychiatry (1997) 58(1):30-31.
   PubMedGoogle Scholar
• LANDY S, MCGINNIS J, CURLIN D, LAIZURE SC: Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache (1999) 39(1):28-32.
   PubMed Web of Science ®Google Scholar
• RAMPELLO L, ALVANO A, CHIECHIO S et al.: Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology (2004) 50(4):322-328.
   PubMed Web of Science ®Google Scholar
• OZYALCIN SN, TALU GK, KIZILTAN E, YUCEL B, ERTAS M, DISCI R: The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache (2005) 45(2):144-152.
   PubMed Web of Science ®Google Scholar
• MITCHELL PB: Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf. (1997) 17:390-406.
   PubMed Web of Science ®Google Scholar
• SOLAI LK, MULSANT BH, POLLOCK BG: Selective reuptake inhibitors for late-life depression: a comparative review. Drugs Aging (2001) 18(5):355-368.
   PubMed Web of Science ®Google Scholar
• SCORDO MG, SPINA E, DAHL ML, GATTI G, PERUCCA E: Influence of CYP2C9 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin. Pharmacol. Toxicol. (2005) 97(5):296-301.
   PubMed Web of Science ®Google Scholar
• MANDRIOLI R, FORTI GC, RAGGI MA: Fluoxetine metabolism and pharmacological interactions: the role of cytochrome P450. Curr. Drug Metab. (2006) 7(2):127-133.
   PubMed Web of Science ®Google Scholar
• HIEMKE C, HARTTER S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. (2000) 85(1):11-26.
   PubMed Web of Science ®Google Scholar
• KOBAVASHI K, ISHIZUKA T, SHIMADA N, YOSHIMURAY, KAMIJIMA K, CHIBA K: Sertraline N-demethylation is catalized by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab. Dispos. (1999) 27(7):763-766.
   PubMed Web of Science ®Google Scholar
• BERTELSEN KM, VENKATAKRISHNAN K, VON-MOLTKE LL, OBACH RS, GREENBLATT DJ: Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. (2003) 31(3):289-293.
   PubMed Web of Science ®Google Scholar
• RUDBERG I, HENDSET M, UTHUS LH, MOLDEN E, REFSUM H: Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther. Drug Monit. (2006) 28(1):102-105.
   PubMed Web of Science ®Google Scholar
• MILNE RJ, GOA KL: Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs (1991) 41:450-477.
   PubMed Web of Science ®Google Scholar
• HOLLIDAY SM, BENFIELD P: Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs (1995) 49:280-294.
   PubMed Web of Science ®Google Scholar
• PERUCCA E: Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. (2005) 61(3):246-255.
   Web of Science ®Google Scholar
• ANDREWS CO, FISHER JH: Gabapentin: a new agent for the management of epilepsy. Ann. Pharmacother. (1994) 28:1188-1196.
   PubMed Web of Science ®Google Scholar
• HAIG GM, BOCKBRADER HN, WESCHE DL et al.: Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J. Clin. Pharmacol. (2001) 41:507-514.
   PubMed Web of Science ®Google Scholar
• Product information: Neurontin®, gabapentin. Pfizer, New York, NY, USA (2002).
   Google Scholar
• TOMSON T, IOHANNESSEN SI: Therapeutic monitoring of the new antiepileptic drugs. Eur. J. Clin. Pharmacol. (2000) 55(10):697-705.
   PubMed Web of Science ®Google Scholar
• PERUCCA E: The clinical pharmacology of the new antiepileptic drugs. Pharmacol. Res. (1993) 28:89-106.
   PubMed Web of Science ®Google Scholar
• CORRIGAN BW, HERMANN D, BURGER P et al.: An analysis of exposure response data for pregabalin: a novel therapy for the treatment of diabetic neuropathic pain. Clin. Pharmacol. Ther. (2001) 69(2):69.
   Google Scholar
• BRODIE MJ, WILSON EA, WESCHE DL et al.: Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia (2005) 46(9):1407-1413.
   PubMed Web of Science ®Google Scholar
• PERUCCA E, BIALER M: The clinical pharmacokinetics of the newer antiepileptic drugs: focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. (1996) 31:29-46.
   PubMed Web of Science ®Google Scholar
• BENEDETTI MS: Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam. Clin. Pharmacol. (2000) 14(4):301-319.
   PubMed Web of Science ®Google Scholar
• CRAWFORD P: Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs (2002) 16:263-272.
   PubMed Web of Science ®Google Scholar
• ZACCARA G, MESSORI A, MORONI F: Clinical pharmacokinetics of valproic acid – 1988. Clin. Pharmacokinet. (1988) 15:367-389.
   PubMed Web of Science ®Google Scholar
• STEPHEN LJ: Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging (2003) 20(2):141-152.
   PubMed Web of Science ®Google Scholar
• SPROULE BA, HARDY BG, SHULMAN KI: Differential pharmacokinetics of lithium in elderly patients. Drugs Aging (2000) 16:165-177.
   PubMed Web of Science ®Google Scholar
• JUURLINK DN, MAMDANI MM, KOPP A, ROCHON PA, SCHULMAN K, REDLMIR DA: Drug-induced lithium toxicity in the elderly: a population based study. J. Am. Geriatr. Soc. (2004) 52:794-798.
   PubMed Web of Science ®Google Scholar
• BURNS RS, GOPINATHAN G, HUMPEL M et al.: Disposition of oral lisuride in Parkinson's disease. Clin. Pharmacol. Ther. (1984) 35:548-556.
   PubMed Web of Science ®Google Scholar
• KANTO J: Clinical pharmacokinetics of ergotamine, dihydroergotamine, ergotoxine, bromocriptine, methysergide, and lergotrile. Int. J. Clin. Pharmacol. Ther. Toxicol. (1983) 21:135-142.
   PubMedGoogle Scholar
• Product information: VFEND®, voriconazole tablets and injection. Pfizer, New York, NY, USA (2002).
   Google Scholar
• LEROY F, ASSEMAN P, PRUVOST P et al.: Dihydroergotamine-erythromycin- induced ergotism (letter). Ann. Intern. Med. (1988) 109:249.
   PubMed Web of Science ®Google Scholar
• PARDO-REY C, YEBRA M, BORALLO M et al.: Irreversible coma, ergotamine and ritonavir. Clin. Infect. Dis. (2003) 37(5):72-73.
   Google Scholar
• CLELAND PG, BARNES D, ELRINGTON GM, LOIZOU LA, RAWES GD: Studies for assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur. Neurol. (1997) 38(1):31-38.
   PubMed Web of Science ®Google Scholar
• BEGG EJ, ATKINSON HC, GIANARAKIS N: The pharmacokinetics of corticosteroid agents. Med. J. Aust. (1987) 146:37-41.
   PubMed Web of Science ®Google Scholar
• VARIS T, KIVISTO K, BACKMAN J et al.: The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin. Pharmacol. Ther. (2000) 68:487-494.
   PubMed Web of Science ®Google Scholar
• TOTH GG, KLOOSTERMAN C, UGES DRA et al.: Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther. Drug Monit. (1999) 21:532-535.
   PubMed Web of Science ®Google Scholar
• ZURBONSEN K, BRESOLLE F, SOLASSO I, ARAGON PJ, CULINE S, PINGUET F: Simultaneous determination of dexamethasone and 6 beta-hydroxymethasone in urine using solid-phase extraction and liquid chromatography: applications to in vivo measurement of cytochrome P450 3A4 activity. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. (2004) 804(2):412-419.
   Google Scholar
• FREY B, FREY FJ: Clinical pharmacokinetics of prednisone and prednisolone. Clin. Pharmacokinet. (1990) 19:126-146.
   PubMed Web of Science ®Google Scholar
• OTHMER SC, OTHMER E, VARANKA TM, STRONG DM: Refractory migraine headache controlled with alprazolam: case report. J. Clin. Psychiatry (1985) 46(11):494-495.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, HARMATZ JS, SHADER RI: Clinical pharmacokinetics of the newer benzodiazepines. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Clin. Pharmacokinet. (1991) 21:164-177.
   Google Scholar
• GALETIN A, HOUSTON JB: Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes – impact on prediction of first-pass metabolism. J. Pharmacol. Exp. Ther. (2006) 318(3):1220-1229.
   PubMed Web of Science ®Google Scholar
• GARZONE PD, KROBOTH PD: Pharmacokinetics of the newer benzodiazepines. Clin. Pharmacokinet. (1989) 16:337-364.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF AJ, BRYSON HM: Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs (1997) 53(3):435-452.
   PubMed Web of Science ®Google Scholar
• Product information: Zanaflex®, tizanidine hydrochloride tablets. Acorda Therapeutics, Hawthorne, New York, USA (2004).
   Google Scholar
• GRANFORS MT, BACKMAN JT, NEUVONEN M et al.: Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin. Pharmacol. Ther. (2004) 76(6):598-606.
   PubMed Web of Science ®Google Scholar
• MOMO K, DOKI K, HOSONO H et al.: Drug interaction of tizanidine and fluvoxamine (letter). Clin. Pharmacol. Ther. (2004) 76(5):509-510.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL T, EZRA D: Calcium antagonists. Drug interactions of clinical significance. Drug Saf. (1995) 13(3):157-187.
   PubMed Web of Science ®Google Scholar
• MOLDEN E, GARCIA BH, BRAATHEN P, EGGEN AE: Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur. J. Clin. Pharmacol. (2005) 61(2):119-125.
   PubMed Web of Science ®Google Scholar
• ZHOU S, CHAN E, PAN SQ, HUANG M, LEE EJ: Pharmacokinetic interactions of drugs with St John's Wort. J. Psychopharmacol. (2004) 18(2):262-276.
   PubMed Web of Science ®Google Scholar
• TAKIYA L, PICCININI LC, KAMATH V: Safety and efficacy of eletriptan in the treatment of acute migraine. Pharmacotherapy (2006) 26(1):115-128.
   PubMed Web of Science ®Google Scholar
• ZHOU S, YUNG-CHAN S, CHER-GOH B et al.: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. (2005) 44(3):279-304.
   PubMed Web of Science ®Google Scholar
• MANZONI GC, TERZANO MG, BONO G, MICIELI G, MARTUCCI N, NAPPI G: Cluster headache – clinical findings in 180 patients. Cephalalgia (1983) 3(1):21-30.
   PubMed Web of Science ®Google Scholar
• BARTHA L, MARKSTEINER J, BAUER G, BENKE T: Persistent cognitive deficits associated with lithium intoxication: a neuropsychological case description. Cortex (2002) 38(5):743-752.
   PubMed Web of Science ®Google Scholar
• ABARCA J, COLON LR, WANG VS, MALONE DC, MURPHY JE, ARMSTRONG EP: Evaluation of the performance of drug–drug interaction screening software in community and hospital pharmacies. J. Manag. Care Pharm. (2006) 12(5):383-389.
   PubMed Web of Science ®Google Scholar
• PERKINS NA, MURPHY JE, MALONE DC, ARMSTRONG EP: Performance of drug–drug interaction software for personal digital assistants. Ann. Pharmacother. (2006) 40(5):850-855.
   PubMed Web of Science ®Google Scholar
• BAX ND, TUCKER GT, LENNARD MS et al.: The impairment of lidocaine clearance by propranolol – major contribution from enzyme inhibition. Br. J. Clin. Pharmacol. (1985) 19:597-603.
   PubMed Web of Science ®Google Scholar
• SILVER JM, YUDOFSKY SC, KOGAN M et al.: Elevation of thioridazine plasma levels by propranolol. Am. J. Psychiatry (1986) 143:1290-1292.
   PubMed Web of Science ®Google Scholar
• RATNAPALAN S, GRIFFITHS K, MOLDOVAN COSTEI A et al.: Digoxin–carvedilol interactions in children. J. Pediatr. (2003) 142:572-574.
   PubMed Web of Science ®Google Scholar
• DEVANE CL: Pharmacokinetics of the newer antidepressants: clinical relevance. Am. J. Med. (1994) 97(Suppl. 6A):13-23.
   Web of Science ®Google Scholar
• KOWEY PR, KIRSTEN EB, FU CH et al.: Interaction between propranolol and propafenone in healthy volunteers. J. Clin. Pharmacol. (1989) 29:512-517.
   PubMed Web of Science ®Google Scholar
• WAGNER F, KALUSCHE D, TRENK D et al.: Drug interaction between propafenone and metoprolol. Br. J. Clin. Pharmacol. (1987) 24:213-220.
   PubMed Web of Science ®Google Scholar
• ZHOU HH, ANTHONY LB, RODEN DM et al.: Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin. Pharmacol. Ther. (1990) 47:686-693.
   PubMed Web of Science ®Google Scholar
• LEEMANN TD, DEVI KP, DAYER P: Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)- metoprolol. Eur. J. Clin. Pharmacol. (1993) 45:65-71.
   PubMed Web of Science ®Google Scholar
• HERMAN RJ, NAKAMURA K, WILKINSON GR et al.: Induction of propranolol metabolism by rifampin. Br. J. Clin. Pharmacol. (1983) 16:565-569.
   PubMed Web of Science ®Google Scholar
• BENNETT PN, JOHN VA, WHITMARSH VB: Effect of rifampicin on metoprolol and antipyrine kinetics. Br. J. Clin. Pharmacol. (1982) 13:387-391.
   PubMed Web of Science ®Google Scholar
• PISCITELLI S, BURSTEIN A, CHAITT D et al.: Indinavir concentrations and St. John's Wort. Lancet (2000) 355:547-548.
   PubMed Web of Science ®Google Scholar
• Product information: Zyflo® Filmtab, zileuton. Abbott Laboratories, North Chicago, IL, USA (1996).
   Google Scholar
• LUBIC SP, NGUYEN PV, DAVE B et al.: Antiarrhythmic agent amiodarone possesses calcium channel blocker properties. J. Cardiovasc. Pharmacol. (1994) 24:707-714.
   PubMed Web of Science ®Google Scholar
• MCCOURTY JC, SILAS JH, TUCKER GT et al.: The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. Br. J. Clin. Pharmacol. (1988) 25:349-357.
   PubMed Web of Science ®Google Scholar
• FRIEDEL HA, SORKIN EM: Nisoldipine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension, and related cardiovascular disorders. Drugs (1988) 36:682-731.
   PubMed Web of Science ®Google Scholar
• GLESBY MJ, ABERG JA, KENDALL MA et al.; ADULT AIDS CLINICAL TRIALS GROUP A5159 PROTOCOL TEAM: Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin. Pharmacol. Ther. (2005) 78(2):143-153.
   PubMed Web of Science ®Google Scholar
• TARTARA A, GALIMBERTI CA, MANNI R et al.: Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br. J. Clin. Pharmacol. (1991) 32(3):335-340.
   PubMed Web of Science ®Google Scholar
• CAPEWELL S, FREESTONE S, CRITCHLEY JA et al.: Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet (1988) 2:480-482.
   PubMed Web of Science ®Google Scholar
• TADA Y, TSUDA Y, OTSUKA T et al.: Case report: nifedipine–rifampin interaction attenuates the effect on blood pressure in a patient with essential hypertension. Am. J. Med. Sci. (1992) 303:25-27.
   PubMed Web of Science ®Google Scholar
• TANNERGREN C, ENGMAN H, KNUTSON L et al.: St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin. Pharmacol. Ther. (2004) 75:298-309.
   PubMed Web of Science ®Google Scholar
• Product information: Invirase®, saquinavir mesylate. Roche Laboratories, Nutley, NJ, USA (1997).
   Google Scholar
• Product information: Synercid® I.V., quinupristin and dalfopristin. Rhone-Poulenc Rorer Pharmaceuticals, Collegeville, PA, USA (1999).
   Google Scholar
• RAY WA, MURRAY KT, MEREDITH S et al.: Oral erythromycin and the risk of sudden death from cardiac causes. N. Engl. J. Med. (2004) 351(11):1089-1096.
   PubMed Web of Science ®Google Scholar
• KANTOLA T, KIVISTO KT, NEUVONEN PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. (1998) 64:177-182.
   PubMed Web of Science ®Google Scholar
• REED M, WALL GC, SHAH NP et al.: Verapamil toxicity resulting from a probable interaction with telithromycin. Ann. Pharmacother. (2005) 39:357-360.
   PubMed Web of Science ®Google Scholar
• LAMBERG TS, KIVISTO KT, NEUVONEN PJ: Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin. Pharmacol. Ther. (1998) 63:640-645.
   PubMed Web of Science ®Google Scholar
• SUMMERS MA, MOORE JL, MCAULEY JW: Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann. Pharmacother. (2004) 38:1631-1634.
   PubMed Web of Science ®Google Scholar
• STEENBERGEN JA, STAUFFER VL: Potential macrolide interaction with verapamil (letter). Ann. Pharmacother. (1998) 32:387-388.
   PubMedGoogle Scholar
• MAGGIO TG, BARTELS DW: Increased cyclosporine blood concentrations due to verapamil administration. Drug Intell. Clin. Pharm. (1988) 22:705-707.
   PubMedGoogle Scholar
• Product information: Relpax®, eletriptan hydrobromide tablets. Pfizer, New York, NY, USA (2002).
   Google Scholar
• Product information: Sporanox®, itraconazole. Janssen Pharmaceutica Products, L.P., Titusville, New Jersey, USA (2002).
   Google Scholar
• BACKMAN JT, OLKKOLA KT, ARANKO K et al.: Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br. J. Clin. Pharmacol. (1994) 37:221-225.
   PubMed Web of Science ®Google Scholar
• Product information: Viramune®, nevirapine. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA (2004).
   Google Scholar
• Product information: Adalat®, nifedipine extended release tablets. Schering, Kenilworth, NJ, USA, (2004).
   Google Scholar
• EPSTEIN SE, ROSING DR: Verapamil: its potential for causing serious complications in patients with hypertropic cardiomyopathy. Circulation (1981) 64:437-441.
   PubMed Web of Science ®Google Scholar
• Product information: Rapamune®, sirolimus, oral solution and tablets. Wyeth Pharmaceuticals, Philadelphia, PA, USA (2005).
   Google Scholar
• WING LMH, MINERS JO, LILLYWHITE KJ: Verapamil disposition – effects of sulfinpyrazone and cimetidine. Br. J. Clin. Pharmacol. (1985) 19:385-391.
   PubMed Web of Science ®Google Scholar
• Product information: Prograf®, tacrolimus. Fujisawa USA, Deerfield, IL, USA (1994).
   Google Scholar
• Product information: Agenerase®, amprenavir. Glaxo Wellcome, Research Triangle Park, NC, USA (2000).
   Google Scholar
• ROBINSON R, NAHATA M, OLSHEFSKI R: Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann. Pharmacother. (2000) 34:1406-1409.
   PubMed Web of Science ®Google Scholar
• KANTOR SJ, GLASSMAN AH, BIGGER JT Jr et al.: The cardiac effects of therapeutic plasma concentrations of imipramine. Am. J. Psychiatry (1978) 135:534-538.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB D: Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress. Anxiety (2001) 13(1):50-52.
   PubMed Web of Science ®Google Scholar
• LEINONEN E, LILLSUNDE P, LAUKKANEN V et al.: Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J. Clin. Psychopharmacol. (1991) 11:313-318.
   PubMed Web of Science ®Google Scholar
• MILLER DD, SAWYER JB, DUFFY JP: Cimetidine's effect on steady-state serum nortriptyline concentrations. Drug Intell. Clin. Pharm. (1983) 17(12):904-905.
   PubMedGoogle Scholar
• WILLIAMS JR, GRIFFIN JP, PARKINS A: Effect of concomitantly administered drugs on the control of long term anticoagulant therapy. QJM (1976) 45:63-73.
   PubMed Web of Science ®Google Scholar
• PERUCCA E, RICHENS A: Interaction between phenytoin and imipramine. Br. J. Clin. Pharmacol. (1977) 4:485-486.
   PubMed Web of Science ®Google Scholar
• ROOTS I, JOHNE A, SCHMIDER J et al.: Interaction of a herbal extract from St. John's Wort with amitriptyline and its metabolites (abstract). Clin. Pharmacol. Ther. (2000) 67(2):159.
   Web of Science ®Google Scholar
• WALLEY T, PIRMOHAMED M, PROUDLOVE C et al.: Interaction of metoprolol and fluoxetine. Lancet (1993) 341:967-968.
   PubMed Web of Science ®Google Scholar
• COPLAN JD, GORMAN JM: Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am. J. Psychiatry (1993) 150:837.
   PubMed Web of Science ®Google Scholar
• RIESENMAN C: Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy (1995) 15(Suppl. 6 part 2):84-99.
   PubMed Web of Science ®Google Scholar
• CHOLLET CAS, ANDREATINI R: Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality. J. Clin. Psychiatry (2003) 64(10):1268-1269.
   PubMed Web of Science ®Google Scholar
• POLLAK PT, SKETRIS IS, MACKENZIE SL et al.: Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann. Pharmacother. (1995) 29:486-488.
   PubMed Web of Science ®Google Scholar
• STEVENS JC, WRIGHTON SA: Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochrome P450. J. Pharmacol. Exp. Ther. (1993) 266:964-971.
   PubMed Web of Science ®Google Scholar
• BENAZZI F: Urinary retention with fluoxetine-haloperidol combination in a young patient. Can. J. Psychiatry (1996) 41:606-607.
   PubMedGoogle Scholar
• CAI WM, CHEN B, ZHOU Y et al.: Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. Clin. Pharmacol. Ther. (1999) 66:516-521.
   PubMed Web of Science ®Google Scholar
• PRESKORN SH, ALDERMAN J, CHUNG M et al.: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin. Psychopharmacol. (1994) 14:90-98.
   PubMed Web of Science ®Google Scholar
• BERGSTROM RF, GOLDBERG MJ, CERIMELE BJ et al.: Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin. Pharmacol. Ther. (1997) 62:643-651.
   PubMed Web of Science ®Google Scholar
• REEVES RR, BULLEN JA: Serotonin syndrome produced by paroxetine and low-dose trazodone (letter). Psychosomatics (1995) 36:159-160.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, PRESKORN SH, COTREAU MM et al.: Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin. Pharmacol. Ther. (1992) 52:479-486.
   PubMed Web of Science ®Google Scholar
• PEARSON HJ: Interaction of fluoxetine with carbamazepine (letter). J. Clin. Psychiatry (1990) 51:126.
   PubMed Web of Science ®Google Scholar
• CENTORRINO F, BALDESSARINI RJ, FRANKENBURG FR et al.: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry (1996) 153:820-822.
   PubMed Web of Science ®Google Scholar
• KURLAN R: Acute parkinsonism induced by the combination of a serotonin reuptake inhibitor and a neuroleptic in adults with Tourette's syndrome. Mov. Disord. (1998) 13:178-179.
   PubMed Web of Science ®Google Scholar
• WOODS DJ, COULTER DM, PILLANS P: Interaction of phenytoin and fluoxetine. NZ Med. J. (1994) 107:19.
   PubMedGoogle Scholar
• NEMEROFF CB, DEVANE CL, POLLOCK BG: Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry (1996) 153:311-320.
   PubMed Web of Science ®Google Scholar
• MORRIS R, BLACK A, LAM E et al.: Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther. Drug Monit. (2000) 22:656-660.
   PubMed Web of Science ®Google Scholar
• ERIKSSON AS, BOREUS LO: No increase in carbamazepine-10,11-epoxide during addition of lamotrigine treatment in children. Ther. Drug Monit. (1997) 19:499-501.
   PubMed Web of Science ®Google Scholar
• GOA KL, ROSS SR, CHRISP P: Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs (1993) 46:152-176.
   PubMed Web of Science ®Google Scholar
• SIDHU J, BULSARA S, JOB S, PHILIPSON R: A bidirectional pharmacokinetic interaction study of lamotrigine and the combined oral contraceptive pill in healthy subjects. Epilepsia (2004) 45(Suppl. 7):330.
   Google Scholar
• KAUFMAN KR, GERNER R: Lamotrigine toxicity secondary to sertraline. Seizure (1998) 7:163-165.
   PubMed Web of Science ®Google Scholar
• WILENSKY AJ, OJEMANN LM, CHMELIR T et al.: Topiramate pharmacokinetics in epileptic patients receiving carbamazepine. Epilepsia (1989) 30:645-646.
   Google Scholar
• ROSENFELD WE, DOOSE DR, WALKER SA et al.: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia (1997) 38:317-323.
   PubMed Web of Science ®Google Scholar
• Product information: Topamax®, topiramate. Ortho-McNeil Pharmaceutical, Raritan, NJ, USA (2003).
   Google Scholar
• HACHAD H, RAGUENEAU-MAJLESSI I, LEVY R: New antiepileptic drugs: review of drug interactions. Ther. Drug Monit. (2002) 24:91-103.
   PubMed Web of Science ®Google Scholar
• SACHDEO RC, SACHDEO SK, WALKER SA et al.: Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia (1996) 37:774-780.
   PubMed Web of Science ®Google Scholar
• LATOUR P, BIRABEN A, POLARD E et al.: Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both? Hum. Psychopharmacol. Clin. Exp. (2004) 19:193-203.
   PubMed Web of Science ®Google Scholar
• YUKAWA E, HIGUCHI S, AOYAMA T: The effect of concurrent administration of sodium valproate on serum levels of primidone and its metabolite phenobarbital. J. Clin. Pharm. Ther. (1989) 14:387-392.
   PubMed Web of Science ®Google Scholar
• PARMEGGIANI A, RIVA R, POSAR A et al.: Possible interaction between acyclovir and antiepileptic treatment. Ther. Drug. Monit. (1995) 17:312-315.
   PubMed Web of Science ®Google Scholar
• FEHR C, GRUNDER G, HIEMKE C et al.: Increase in serum clomipramine concentrations caused by valproate. J. Clin. Psychopharmacol. (2000) 20(4):493-494.
   PubMed Web of Science ®Google Scholar
• FARREL K, ORR JM, ABBOTT FS et al.: The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children. J. Pediatr. (1982) 101:142-144.
   PubMed Web of Science ®Google Scholar
• MATTSON GF, MATTSON RH, CRAMER JA: Interaction between valproic acid and carbamazepine: an in vitro study of protein binding. Ther. Drug Monit. (1982) 4:181-184.
   PubMed Web of Science ®Google Scholar
• OMODO K, MURAKAMI T, YUMOTO R et al.: Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human. J. Pharm. Sci. (2005) 94:1685-1693.
   PubMed Web of Science ®Google Scholar
• IKEDA H, MURAKAMI T, TAKANO M, USUI T, KIHIRA K: Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient. Br. J. Clin. Pharmacol. (2005) 59:5937.
   Google Scholar
• BOURGEOIS BF: Pharmacologic interactions between valproate and other drugs. Am. J. Med. (1988) 84(Suppl. 1A):29-33.
   PubMedGoogle Scholar
• MALLOY MJ, RAVIS WR, PENNELL AT et al.: Effect of cholestyramine resin on single dose valproate pharmacokinetics. Int. J. Clin. Pharmacol. Ther. (1996) 34:208-211.
   PubMed Web of Science ®Google Scholar
• REDINGTON K, WELLS C, PETITO F: Erythromycin and valproate interaction (letter). Ann. Intern. Med. (1992) 116:877-878.
   PubMed Web of Science ®Google Scholar
• WAGNER ML, GRAVES NM, LEPPIK IE et al.: The effect of felbamate on valproic acid disposition. Pharmacotherapy (1992) 12:260.
   Google Scholar
• DOCKWEILER U: Isoniazid-induced valproic-acid toxicity, or vice versa (letter). Lancet (1987) 2:152.
   PubMed Web of Science ®Google Scholar
• ANDERSON GD, GIDAL BE, KANTOR ED et al.: Lorazepam–valproate interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia (1994) 35:221-225.
   PubMed Web of Science ®Google Scholar
• Product information: Depakote® ER, divalproex sodium extended-release tablets. Abbott Laboratories, North Chicago, IL, USA (2003).
   Google Scholar
• LEUNG M, REMICK R: Potential drug interaction between lithium and valsartan. J. Clin. Pharmacol. (2000) 20(3):392-393.
   Web of Science ®Google Scholar
• Product information: Lithium Carbonate. Roxane Laboratories, Columbus, OH, USA (2002).
   Google Scholar
• STEVENSON RN, BLANSHARD C, PATTERSON DLH: Ventricular fibrillation due to lithium withdrawal – an interaction with chlorpromazine? Postgrad. Med. J. (1989) 65:936-938.
   PubMed Web of Science ®Google Scholar
• SINGER I, ROTENBERG P: Mechanisms of lithium action. N. Engl. J. Med. (1973) 289:254.
   PubMed Web of Science ®Google Scholar
• GRIFFIN JH, HAHN SM: Lisinopril-induced lithium toxicity (letter). DICP (1991) 25:101.
   PubMedGoogle Scholar
• PASSIU G, BOCCHETTA A, MARTINELLI V et al.: Calcitonin decreases lithium plasma levels in man. Preliminary report. Int. J. Clin. Pharm. Res. (1998) 18:179-181.
   PubMedGoogle Scholar
• JEFFERSON JW: Lithium tremor and caffeine intake: two cases of drinking less and shaking more. J. Clin. Psychiatry (1988) 49:72-73.
   PubMed Web of Science ®Google Scholar
• PHELAN KM, MOSHOLDER AD, LU S: Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J. Clin. Psychiat. (2003) 64:1328-1334.
   PubMed Web of Science ®Google Scholar
• TEICHER MH, ALTESMAN RI, COLE JO et al.: Possible nephrotoxic interaction of lithium and metronidazole (letter). JAMA (1987) 257:3365-3366.
   PubMedGoogle Scholar
• PERLMAN BB: Interaction between lithium salts and ispaghula husk. Lancet (1990) 1:416.
   Google Scholar
• MC-SWIGGAN C: Interaction of lithium and bicarbonate (letter). Med. J. Aust. (1978) 1:38-39.
   Google Scholar
• OHMAN R, SPIGSET O: Serotonin syndrome induced by fluvoxamine–lithium interaction. Pharmacopsychiatry (1993) 26:263-264.
   PubMed Web of Science ®Google Scholar
• SIERLES FS, OSSOWSKI MG: Concurrent use of theophylline and lithium in a patient with chronic obstructive lung disease and bipolar disorder. Am. J. Psychiatry (1982) 139:117-118.
   PubMed Web of Science ®Google Scholar
• Product information: Emend®, aprepitant. Merck & Co., Whitehouse Station, NJ, USA (2003).
   Google Scholar
• Product information: Seroquel®, quetiapine fumurate. AstraZeneca Pharmaceuticals, Wilmington, DE, USA (2001).
   Google Scholar
• EDELMAN J, POTTER JM, HACKETT LP: The effect of intra-articular steroids on plasma salicylate concentrations. Br. J. Clin. Pharmacol. (1986) 21:301-307.
   PubMed Web of Science ®Google Scholar
• LEBRUN-VIGNES B, ARCHER V, DIQUET B et al.: Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br. J. Clin. Pharmacol. (2001) 51:443-450.
   PubMed Web of Science ®Google Scholar
• YOUNG MC, HUGHES IA: Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone. Acta. Paediatr. Scand. (1991) 80:120-124.
   PubMed Web of Science ®Google Scholar
• OLIVESI A: Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed. Pharmacother. (1986) 40:301-308.
   PubMed Web of Science ®Google Scholar
• BACIEWICZ AM, BACIEWICZ FA Jr: Cyclosporine pharmacokinetic drug interactions. Am. J. Surg. (1989) 157:264-271.
   PubMed Web of Science ®Google Scholar
• Product information: Gleevec™, imatinib mesylate tablets. Novartis Pharmaceuticals, East Hanover, NJ, USA (2003).
   Google Scholar
• Product information: Crixivan®, indinavir sulfate. Merck & Co., Whitehouse Station, NJ, USA (2004).
   Google Scholar
• FOST DA, LEUNG DYM, MARTIN RJ et al.: Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J. Allergy Clin. Immunol. (1999) 103:1031-1035.
   PubMed Web of Science ®Google Scholar
• FREY BM, SCHAAD HJ, FREY FJ: Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. Eur. J. Clin. Pharmacol. (1984) 26:505-511.
   PubMed Web of Science ®Google Scholar
• Product information: Biltricide®, praziquantel. Bayer Pharmaceuticals, West Haven, CT, USA (2004).
   Google Scholar
• KEILHOLZ U, GUTHRIE GP Jr: Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am. J. Med. Sci. (1986) 291:280-283.
   PubMed Web of Science ®Google Scholar
• CARRIE F, ROBLOT P, BOUQUET S et al.: Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch. Intern. Med. (1994) 154:1521-1524.
   PubMed Web of Science ®Google Scholar
• Product information: Vesanoid®, tretinoin. Roche Laboratories, Nutley, NJ, USA (2003).
   Google Scholar
• OLKKOLA KT, AHONEN J, NEUVONEN PJ: The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. (1996) 82:511-516.
   PubMed Web of Science ®Google Scholar
• YUAN R, FLOCKHART DA, BALIAN JD: Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J. Clin. Pharmacol. (1999) 39(11):1109-1025.
   PubMed Web of Science ®Google Scholar
• Product information: NIRAVAM™ orally disintegrating tablet, alprazolam orally disintegrating tablet. Schwarz Pharma, Milwaukee, WI, USA (2003).
   Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS et al.: Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin. Pharmacol. Ther. (1998) 64:278-285.
   PubMed Web of Science ®Google Scholar
• ANDERSSON T, CEDERBERG C, EDVARDSSON G et al.: Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. (1990) 47:79-85.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ JS, DONOVAN JL, DEVANE CL et al.: Effect of St John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA (2003) 290(11):1500-1504.
   PubMed Web of Science ®Google Scholar

Websites

• http://ahsnet.org/guidelines.phpPharmacological Management of Acute Attacks. US Headache Consortium (2000).
   Google Scholar
• http//www.bash.org.ukBRITISH ASSOCIATION FOR THE STUDY OF HEADACHE: Guidelines for all doctors in the diagnosis and management of migraine and tension-type headache, 2nd edition (revised August 2004).
   Google Scholar